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Abstract
Development of therapeutics for the central nervous system is one of the most challenging areas
in drug development. This is primarily because, in addition to all of the other complications one
faces in developing new drugs targeting peripheral sites, one must also negotiate the blood-brain
barrier (BBB). There are dozens of strategies to overcome the obstacle of the BBB, but many of
these are bound to fail, barring extreme serendipity, because they are based on an inaccurate or
incomplete picture of the BBB. This article therefore starts with a brief review of the BBB as it
pertains to drug development. It then examines some examples of the delivery of drugs to the
central nervous system that are relevant to Alzheimer's disease, placing emphasis on peptides,
antibodies, and antisense oligonucleotides.
Introduction
This review will first examine some of the history and
basic concepts of brain barriers. It will then discuss the
major mechanisms that promote or retard the passage of
substances from blood to brain. Finally, it will discuss spe-
cific examples of substances that cross the blood-brain
barrier (BBB) and the mechanisms they most influence
their abilities or inabilities to cross the BBB.
Brief history of the blood-brain barrier
The BBB can be viewed as a concept to explain the late
19th century observation that basic dyes injected into the
blood stream failed to stain central nervous system (CNS)
tissues [1]. Early on, many believed that this was simply
because CNS tissue had no affinity for these dyes, but
another theory developed over the decades – that some
barrier prevented the dye from leaving the circulation and
entering the interstitial fluid of the CNS. The leading con-
tender for this barrier was the brain's vasculature. How-
ever, gross inspection and light microscopic studies failed
to show any differences between peripheral and central
blood vessels. It was not until the ultrastructural studies of
Karnovsky and colleagues in the late 1960s and early
1970s that the capillary bed of the brain was found to dif-
fer from peripheral capillary beds in three fundamental
ways: the intercellular spaces between adjacent capillaries
are obliterated by tight junctions; pinocytosis is greatly
decreased; and fenestrations and other intracellular leaks
are essentially absent. Together, these modifications pre-
vent the formation of a plasma ultrafiltrate, and so plasma
proteins such as albumin do not cross from blood into the
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CNS. Because the basic dyes bound tightly to albumin,
they also were unable to enter the CNS.
Parallel barriers exist at the choroid plexus and at most of
the circumventricular organs, the latter barriers formed by
ependymal cells and tanycytes. Together, these barriers
control the exchange of substances between blood and the
CNS, but they also perform functions apart from acting as
a barrier. The inability to produce a plasma ultrafiltrate
means that some other mechanism must be found that
conveys needed nutrients to the CNS. The barriers per-
form this function as well. Specific, saturable transport
systems exist for the blood-to-CNS transport of glucose,
amino acids, vitamins, minerals, fatty acids, electrolytes,
and other substances that are needed by the CNS. Trans-
porters oriented in the CNS-to-blood direction can rid the
CNS of toxins and can act as a functional barrier to circu-
lating substances. Small, lipid soluble substances are also
able to cross the barriers, and a residual leakiness of the
barrier systems (termed the extracellular pathways) can
allow minute amounts of substances to enter the CNS.
Most authorities emphasize that, of these various barriers,
it is the vascular barrier that is of most interest for drug
delivery. This is because no CNS cell is more than about
40 μm from a capillary, and so the whole brain can be
accessed by a substance delivered by way of the vascular
system. Additionally, substances entering the CNS via the
choroid plexus will enter the cerebrospinal fluid (CSF).
These substances can distribute throughout the cranial
CSF, but CSF-to-brain diffusion is limited, making pene-
tration deep into brain potentially problematic. Finally,
the vascular barrier lends itself more readily to in vivo and
in vitro study and analysis than either the choroid plexus
or the tanycytic barriers.
Specific strategies for drug delivery
Dozens of strategies have been devised to deliver drugs
across the BBB. Much attention has been focused on find-
ing a universal delivery system that can carry any desired
drug into the CNS. Some of these have been based on
some understanding of the BBB, whereas others have dis-
regarded essential aspects of BBB function. An alternative
strategy that more closely resembles the traditional
approach to drug development is as follows. Rather than
starting with some universal delivery system for delivering
an undefined drug (for an unknown disease), it starts with
an identified ligand, usually an endogenous substance or
proto-drug, targeted to a known disease. Special character-
istics of the disease may aid or impede drug delivery, and
the ligand can be modified to cross the BBB, which itself
may be modified by the disease [2-4].
BBB drug delivery is complex because there are important
exceptions to every rule and relevant caveats to every
exception. Nevertheless, there are mechanisms that pro-
mote, as well as others that hinder, the passage of a sub-
stance into the CNS. Two important conclusions from this
kind of analysis are: 1) the biggest barrier to delivering a
substance into the CNS may not be the BBB itself, and 2)
very little drug is needed in the CNS to produce a thera-
peutic effect. For example, only about 0.02% of a periph-
erally administered dose of morphine enters the brain,
but that is sufficient to produce analgesia. For most CNS
therapeutics on the market, less than 0.2% of the periph-
eral dose is taken up by brain.
There are a limited number of mechanisms by which sub-
stances cross the BBB. The major mechanisms for delivery
of substances into the CNS are transmembrane diffusion
and saturable transport [5]. Most CNS therapeutics are
small, lipid soluble molecules that are likely to rely upon
transmembrane diffusion to cross the BBB. Although pep-
tides, and even some small proteins, have a measurable
transmembrane diffusion, saturable transporters are lia-
ble to be the most effective mechanism for delivering
these molecules into the CNS. Saturable transporters typ-
ically deliver 10 to 100 times more of their main ligand to
the CNS than would occur with transmembrane diffu-
sion. Substances with a small volume of distribution and
a long residence time in the circulation can slowly enter
the CNS by way of the extracellular pathways. Immune
cells cross the BBB by a vesicular related process: diapede-
sis. The binding and internalization phases of this process
are initiated by lectin-like interactions, that is, by interac-
tions between glycoproteins on the endothelial surface
with glycoproteins on the immune cell surface. Glycopro-
teins themselves can be taken up and transported across
the BBB by the vesicular process of adsorptive endocytosis
[6]. It may be a form of these vesicular mechanisms that
the larger universal carriers are co-opting, just as some
viruses exploit aspects of transport processes to cross the
BBB. Two problems with utilizing diapedesis/vesicular-
like mechanisms are as follows: its reliance on an intimate
cross-talk between the brain endothelial cell and the
immune cell, mediated largely by cytokines, and a lack of
understanding of how vesicles are routed within the cell.
Nevertheless, diapedesis might be an important mecha-
nism for stem cell, immune cell, viral, and drug delivery.
There are numerous mechanisms that can oppose entry of
substances into the brain. These are operable to varying
degrees for a given substance. Besides the physical barrier
of the endothelial cell wall, there are the following obsta-
cles: protein binding in the circulation; enzymatic degra-
dation in the circulation, at the BBB, or within the CNS;
uptake or sequestration by peripheral tissues of the
peripherally administered substance; sequestration by the
capillaries that comprise the BBB; and efflux, or removal,
by CNS-to-blood transporters. Countering these mecha-BMC Neuroscience 2008, 9(Suppl 3):S2 http://www.biomedcentral.com/1471-2202/9/S3/S2
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nisms can turn an ineffective drug into one that is capable
of significant accumulation within the CNS.
Usually, protein binding results in a drastic net decrease in
CNS uptake because only free drug is available to cross the
BBB [7]. Interestingly, it was protein binding of small
basic dyes that led to one of the seminal observations in
describing the BBB, namely that dyes readily entered and
stained the brain when perfused through brain vascula-
ture in the absence of proteins. Protein binding can rarely
assist delivery to the CNS by improving pharmacokinetics
(for example, longer half-life in the circulation, smaller
volume of distribution in peripheral tissues, and protec-
tion from enzymatic degradation). Unfavorable pharma-
cokinetics (such as short half-life, large volume of
distribution, and degradation in the blood and by periph-
eral tissues) probably prevent as many candidate thera-
peutics from entering the CNS as does the physical aspect
of the cell wall forming the BBB. This is especially a prob-
lem for peptides and regulatory proteins. Small, enzymat-
ically stable peptides are capable of crossing the BBB even
in the absence of a saturable transporter in amounts suffi-
cient to affect CNS function.
Efflux transporters have emerged as a major force in drug
development. They transport substances in the CNS-to-
blood direction that would otherwise accumulate in the
CNS. There are numerous efflux transporters, and they are
known to remove many drugs, but P-glycoprotein is the
most studied. Efflux of a drug can be viewed as desirable
because it prevents unwanted CNS side effects (for exam-
ple, loperamide and ivermectin) or undesirable because it
blocks effective delivery of a therapeutic to the brain (for
example, antiretroviral and anti-epileptic drugs). Efflux
from the CNS of the opiate loperamide prevents it from
exerting its analgesic actions but not its constipating
effects on the gastrointestinal tract. Thus, loperamide is
commonly used as a nonsedating treatment for diarrhea.
Efflux of the anthelminthic agent ivermectin prevents it
from exerting otherwise lethal neurotoxic effects. Efflux of
antiretroviral drugs (for example, protease inhibitors) pre-
vents them from effectively treating HIV-1 within the
CNS, allowing virus there to replicate safely and possibly
reinfect the rest of the body. Efflux of anti-epileptics is a
major reason why approximately 30% of epilepsy patients
are resistant to most of the currently available anticonvul-
sants.
Developing drugs for Alzheimer's disease
Drugs currently on the market are traditionally small, rel-
atively lipid-soluble compounds. Thus, these drugs can
cross the BBB by means of transmembrane diffusion. With
the knowledge that such a mechanism can be extended to
small peptides, a series of 'breaker peptides' were devel-
oped. These substances prevent or reverse the oligomeri-
zation and fibrillation of amyloid β protein. They have
been shown to cross the BBB, decreasing the presence of
neurofibrillary tangles, and to reverse cognitive impair-
ments in animal models of Alzheimer's disease (AD) [8].
Passive and active immunization have received much
attention as potential treatments for AD. The main diffi-
culty with antibodies is that they cross the BBB poorly.
This poor penetration of IgG molecules is partly due to
their large size, the lack of a saturable blood-to-brain
transport system, and the likely presence of an effective
brain-to-blood efflux transporter. The main advantages
for antibodies are pharmacokinetic: they have long half-
lives in blood and small volumes of distribution. Thus,
they are ideal for crossing the BBB by way of the extracel-
lular pathways. However, their accumulation in brain is
abbreviated because of an apparent efflux system men-
tioned above. Overcoming this efflux, perhaps with the
use of the IgM class, should allow enhanced accumulation
of antibody in the CNS. In theory, the efflux system could
work toward a therapeutic effect for an antibody with very
high affinity for β amyloid protein. In this scenario, the
benefit of the efflux system in helping to rid the CNS of
amyloid-bound antibody would outweigh the decrease it
caused in antibody accumulation within the CNS.
Saturable transport systems remain the most effective way
to deliver therapeutics to the CNS. The feeding hormones
are an unexpected source of peptides active in cognition.
Many of these cross the BBB by way of saturable transport
systems to exert their effects on the CNS. A recent example
of this is ghrelin, a substance produced by the stomach,
which is transported across the BBB into the hypothala-
mus, where it induces hunger. Ghrelin also crosses the
BBB at the hippocampus, where it increases synaptic den-
sity. Ghrelin has been shown to improve learning and
memory in various models, including AD [9]. Another
example of using a saturable transporter is in the delivery
of phosphorothioate antisense oligonucleotides to the
brain. A nuclease-resistant antisense oligonucleotide
directed against the β amyloid protein region of amyloid
precursor protein can cross the BBB, reduce levels of β
amyloid, and reverse well-established cognitive deficits in
animal models of AD [10].
Conclusion
The development of drugs that can cross the BBB is one of
the greatest challenges in medicine today. However, the
basic mechanisms that govern both entry to, and exclu-
sion of, substances from the CNS are well outlined. How
these mechanisms operate vary among substances and
disease states, potentially adding a dimension of complex-
ity but also of opportunity. New classes of drugs for the
treatment of AD that exploit these mechanisms of BBBPublish with BioMed Central    and   every 
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penetration include peptides, regulatory proteins, anti-
bodies, and antisense oligonucleotides.
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